SPTX — Seaport Therapeutics, Inc. Common Stock stock price, charts and financials

QT75Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
21.39
-0.43-1.97%
OverviewShort InterestFilings
SPTXQT75Seaport Therapeutics, Inc. Common Stock·NASDAQ
21.39-1.97%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26MESO+1.75%$15.13ZYME-3.31%$26.57AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83GPCR-0.28%$35.00
Snapshot
Index-P/E-EPS (ttm)-Insider Own31.17%Shs Outstand53.53MPerf Week-8.35%
Market Cap1.15BForward P/E-EPS next Y-2.61Insider Trans0.00%Shs Float17.51MPerf Month-12.41%
Enterprise Value1.09BPEG-EPS next Q-0.58Inst Own-Short Float5.89%Perf Quarter17.72%
Income-88.05MP/S0.00EPS this Y-Inst Trans-Short Ratio19.48Perf Half Y-
Sales0.00P/B2.71EPS next Y41.39%ROA-19.93%Short Interest3.15MPerf YTD1.86%
Book/sh-P/C-EPS next 5Y-ROE-57.34%52W High28.38 -24.63%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-21.83%52W Low14.85 44.04%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility9.42% 9.02%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)2.01Perf 10Y-
Dividend Ex-Date-Quick Ratio18.00Sales Y/Y TTM-Profit Margin0.00%RSI (14)41.96Recom2.00
Dividend Gr. 3/5Y-Current Ratio18.00EPS Q/Q-SMA20-10.53%Beta0.81Target Price37.33
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-5.69%Rel Volume12.09Prev Close21.82
Employees58LT Debt/Eq-0.03EarningsNov 02SMA2004.96%Avg Volume180.22KPrice21.39
IPO DateMay 01, 2026Option/ShortNo / YesEPS/Sales Surpr.-186.92% -Net Debt/EBITDA0.64Volume2,178,468Change-1.97%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-25-26InitiatedJonesBuy$32
Aug-04-26ReiteratedHC Wainwright & Co.Buy$50
Jul-15-26InitiatedH.CBuy$50
May-26-26InitiatedLeerinkOutperform$35
May-26-26InitiatedStifelBuy$30
May-26-26InitiatedJPMorganOverweight$42
Latest News· Times ET
Sep-14-26
Sep-14-2603:00AM
Seaport Therapeutics to Participate in September Investor Conferencesbusinesswire.com
Sep-10-26
Sep-10-2602:42AM
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price TargetBenzinga
Sep-09-26
Sep-09-2612:17PM
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com
10:00AM
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteersgurufocus.com
03:00AM
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteersbusinesswire.com
Aug-31-26
Aug-31-2607:00AM
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare ConferenceYahoo
Aug-27-26
Aug-27-2603:09PM
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)SeekingAlpha
Aug-20-26
Aug-20-2606:40AM
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO247wallst.com
02:07AM
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price TargetBenzinga
Aug-17-26
Aug-17-2611:45PM
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High – Here’s What Happeneddefenseworld.net
Aug-11-26
Aug-11-2602:27PM
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validationseekingalpha.com
Aug-04-26
Aug-04-2602:26AM
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price TargetBenzinga
Aug-03-26
Aug-03-2603:05AM
Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) EstimateBenzinga
03:00AM
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progressbusinesswire.com
Jul-15-26
Jul-15-2602:42AM
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50Benzinga
Company

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
Total Revenue
0
Cost of Goods Sold Incl. D&A
0
Gross Profit
0
Selling, General and Administrative Excl. Other21
Research and Development66
Other Operating Expense
0
Operating Income-87
Interest Expense
0
Unusual Expense
—
Non-Operating Income (Expense)13
Net Income Before Taxes-74
Income Taxes1
Consolidated Net Income-75
Net Income From Continuing Operations-75
Net Income-75
EPS (Recurring)-1.94
EPS (Basic, Before Extraordinaries)-1.94
EPS (Diluted)-1.94
EBITDA-86
Other After Tax Adjustments
—
Stock Option Compensation Expense
—
Price To Earnings Ratio
—
Price To Sales Ratio
—
Gross Margin
—
Operating Margin
—
Net Margin
—
Shares Outstanding39
Market Capitalization
—
Operating Lease Expense
—
Insider Trading Volume
$29.73$25.64$21.55$17.45$13.36● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.